Medication info

Telmisartan and Rosuvastatin Tablet 40/10 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
IlYang Biopharm Co., Ltd.
Appearance
Light orange oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTPX3]
Approval status
Expired

MFDS item code 202101824 · Approved 2021.02.24

This product's status changed to Expired on 2026.02.24. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, reduction of cardiovascular risk, and inhibition of atherosclerosis progression
Who takes it
Adults
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg once daily by mouth as telmisartan; depending on the patient, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered in combination with a thiazide diuretic such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg once daily by mouth. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, and most patients are controlled at this dose. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, whereas an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product with the same amount of each active ingredient) for convenience of administration.

Ingredients

Manufacturer
IlYang Biopharm Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, reduction of cardiovascular risk, and inhibition of atherosclerosis progression

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medicine is used for patients who need to take telmisartan and rosuvastatin simultaneously. Telmisartan helps in the treatment of essential hypertension and reduces the risk of cardiovascular diseases. It particularly reduces the risk of myocardial infarction, stroke, and cardiovascular death in the elderly who are at high risk for cardiovascular disease or in whom ACE inhibitors cannot be used. Meanwhile, rosuvastatin is used for the treatment of hypercholesterolemia and dyslipidemia and is effective as an adjunctive therapy when dietary control is insufficient. It also helps to reduce the risk of cardiovascular diseases, thus lowering the risks of stroke, myocardial infarction, and arterial revascularization procedures. The combined use of these two medications is used to improve cardiovascular health.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg once daily by mouth as telmisartan; depending on the patient, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered in combination with a thiazide diuretic such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg once daily by mouth. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, and most patients are controlled at this dose. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, whereas an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product with the same amount of each active ingredient) for convenience of administration.

Precautions

This medicine can pose serious risks to the fetus during pregnancy, so it must be discontinued immediately if pregnancy is confirmed. Patients who are allergic to this medication, have severely impaired liver or kidney function, or have muscle-related diseases should not use this medication. Women of childbearing potential must ensure appropriate contraception and can only take this medication when it is judged that the chance of pregnancy is low. Patients with mildly impaired liver function, elderly patients, or those with high potassium levels must use this medication with caution. This medication may cause muscle-related side effects such as myalgia or myopathy, so if muscle pain or weakness occurs, consult a physician immediately. This medication may affect liver function, so regular liver function tests should be done before and during treatment. As this medication lowers blood pressure, symptoms of hypotension (dizziness, fainting, etc.) may occur, and caution is necessary. This medication may interact with other medications, so if you are taking other medications, you must inform your physician or pharmacist. It is advisable to avoid alcohol while taking this medication, and patients with liver disease or heavy alcohol consumption should exercise extra caution. This medication is not recommended for children as safety and efficacy have not been established. In case of overdose, symptoms such as hypotension, cardiac arrhythmias, and worsening kidney function may present, so immediate medical attention is required. Caution is required when driving or operating machinery, as dizziness or drowsiness may occur.

Side effects

Elevated ALT, Elevated AST, Elevated serum creatine phosphokinase (CPK), Dizziness, Pruritus, Dyspepsia, Oral paresthesia, Musculoskeletal rigidity, Acne, Nasopharyngitis, Increased serum potassium, Glycosuria, Dysuria, Rhinitis, Pharyngeal discomfort, Pulmonary disease, Unspecified gastrointestinal disorder, Benign gastrointestinal neoplasm, Hemorrhoids, Skeletal pain, Osteoporosis, Sensory impairment, Movement disorders, Atherosclerosis, Frequent urination, Tinnitus, Hearing loss, Halitosis, Fatty liver, Upper respiratory infection, Urinary tract infection, Sepsis, Anemia, Thrombocytopenia, Eosinophilia, Hypersensitivity, Anaphylactic reaction, Hyperkalemia, Hypoglycemia, Depression, Insomnia, Anxiety, Syncope, Visual disturbances, Dizziness, Bradycardia, Tachycardia, Hypotension, Orthostatic hypotension, Dyspnea, Abdominal pain, Diarrhea, Abdominal bloating, Vomiting, Abdominal discomfort, Dry mouth, Abnormal liver function, Liver impairment, Increased sweating, Rash, Erythema, Angioedema, Drug rash, Toxic skin rash, Eczema, Urticaria, Myalgia, Lumbago, Muscle cramps, Arthralgia, Limb pain, Tendon pain, Acute kidney failure, Chest pain, Asthenia, Influenza-like illness, Increased serum creatinine, Increased serum uric acid, Elevated liver enzymes, Increased serum CK, Decreased hemoglobin, Headache, Facial spasms, Paresthesia, Paralysis, Cough, Hyperventilation, Pneumonia, Flushing, Erectile dysfunction, Anorexia, Arrhythmia, Weakness, Edema, Decreased libido, Facial edema, Rash, Alopecia, Conjunctivitis, Tinnitus, Petechiae, Constipation, Nausea, Pancreatitis, Urticaria, Myopathy, Rhabdomyolysis, Asthenia, Polyneuropathy, Amnesia, Peripheral neuropathy, Diarrhea, Thrombocytopenia, Jaundice, Hepatitis, Stevens-Johnson syndrome, Drug reaction with eosinophilia and systemic symptoms, Lupus-like syndrome, Muscle rupture, Arthritis, Immune-mediated necrotizing myopathy, Hematuria, Edema, Depression, Sleep disorders, Sexual dysfunction, Gynecomastia, Interstitial lung disease, Fatal and non-fatal liver failure, Headache, Dizziness, Cough, Palpitations, Fatigue, Nausea, Inadequate efficacy, Myalgia, Arthralgia, Increased CK, Constipation, Increased AST, Numbness, Paresthesia, Chest discomfort, Abdominal pain, Diarrhea, Anorexia, Abdominal bloating, Abnormal liver function tests, Syncope, Generalized pain, Muscle cramps, Gout, Erectile dysfunction, Acute kidney failure, Oliguria, Thrombocytopenia, Increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is best to keep the storage temperature between 1°C and 30°C at room temperature.

Appearance and packaging

Appearance

Light orange oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTPX3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.